clinical trial · NCT07493512
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer (mCRPC)Xaluritamig
brief summary
The primary objective of this trial is to determine the safety profile of xaluritamig at the proposed regimen in adult participants with metastatic castration-resistant prostate cancer (mCRPC).
started
Apr 28, 2026
primary completion
Jan 30, 2028
completion
Jul 30, 2030
last updated
Jul 2, 2026
official title
A Phase 1b, Open-label Study of Xaluritamig (AMG 509) in Adults With Metastatic Castration-resistant Prostate Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol